Skip to main content
. Author manuscript; available in PMC: 2013 Sep 15.
Published in final edited form as: Clin Cancer Res. 2012 Jul 27;18(18):5099–5109. doi: 10.1158/1078-0432.CCR-12-1590

Table 4.

Top SNPs from Ordinal Analysis

SNP Chr Genea Alleles Discovery
(n=855)
European
Replication (n=154)d
African American
Replication (n=117)d
MAFb OR
(95% CI)
Pc MAF OR
(95% CI)
P MAF OR
(95% CI)
P
rs7001034e 8 FZD3 G/T 0.40 0.57
(0.48–0.69)
3.1 ×10−9
rs7833751f 8 FZD3 G/T 0.40 0.58
(0.49–0.70)
7.5 × 10−9 0.41 1.67f
(0.88–3.19)
0.058
rs5934683 X /SHROOM2 C/T 0.36 1.61
(1.33–1.93)
6.0 × 10−7 0.33 0.99g
(0.54–1.82)
0.49 0.30 1.96g
(0.49–7.89)
0.17
rs2941627 8 /ZFPM2 A/G 0.13 1.91
(1.40–2.51)
3.5 × 10−6 0.15 1.37g
(0.68–2.73)
0.19 0.25 0.49g
(0.24–0.97)
0.021
rs7973533 12 /BCAT1 T/G 0.46 0.66
(0.55–0.79)
8.4 × 10−6 0.44 0.75
(0.47–1.19)
0.11 0.27 1.13
(0.65–1.94)
0.33
a

Intergenic SNPs are denoted by the closest flanking annotated gene.

b

Minor allele frequency (MAF) was calculated within the indicated cohort.

c

P-values are two-sided for discovery analysis and one-sided for replication.

d

As stated in the replication plan, all analyses were exploratory except for the FZD3 SNP.

e

There was no available TaqMan assay for rs7001034 to use in replication studies.

f

This SNP tags rs7001034 in the European population but not in the African American population.

g

Analysis assumed a dominant model.